Back to results
US 12,403,165 B2Granted
Oncolytic immunotherapy by tumor micro-environment remodeling
AssigneeKaliVir Immunotherapeutcs, Inc.
InventorsStephen Howard Thorne, Mingrui Zhang, Daniel J. Byrd
Life of this patent
Estimating the term…
Abstract
The disclosure relates to modified oncolytic viruses. The modified oncolytic viruses of the disclosure comprise modification in the viral genome encoding exogenous nucleic acids to enhance the oncolytic immunotherapy by remodeling the tumor microenvironment and with enhanced systemic delivery. The disclosure further relates to compositions comprising the modified oncolytic viruses, kits containing the same, and methods of using the oncolytic viruses.
Claims27
A modified oncolytic virus comprising:
- an exogenous nucleic acid encoding a fusion protein comprising a metabolic modulating protein, wherein the exogenous nucleic acid encoding for the fusion protein comprises:
- a region encoding for an IL-2 polypeptide, and
- a region encoding for a leptin polypeptide;
- an exogenous nucleic acid encoding a chemokine receptor, wherein the chemokine receptor is CCR2;
- and
- a genetic modification in a viral genome of the modified oncolytic virus, wherein the modified oncolytic virus provides for enhanced tumor volume reduction upon systemic delivery to a subject compared to systemic administration of an otherwise identical oncolytic virus not comprising the exogenous nucleic acid encoding the fusion protein.
3 more elements
Dependencies are inferred from the claim text.